Healthcare entity
All 1 tracked stories fall under one category: market-trends. Jan van de Winkel, Ph.D. is most often covered alongside AbbVie, which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention Jan van de Winkel, Ph.D., all published on July 11, 2026.
Last mentioned: Jul 11, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Jan van de Winkel, Ph.D. is most often covered alongside AbbVie, which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention Jan van de Winkel, Ph.D., all published on July 11, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jan van de Winkel, Ph.D.. Shared-story counts are live from our verified record — not editorial picks.
A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
Jan van de Winkel, Ph.D. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
